ESPE-ESE 2025 10 - 13 May 2025

Long-term efficacy and safety of once-weekly somapacitan in children with growth hormone deficiency: 7-year results from the randomised REAL 3 trial

Authors :

Lars Sävendahl¹; Tadej Battelino²; Michael Højby³; Tina Leunbach³; Paul Saenger⁴; Lawrence Silverman⁵; Reiko Horikawa⁶

Affiliations

View Details Hide Details

Keywords

Rare Endocrine Disorder

Congress poster

Somapacitan